Nexo Therapeutics
Nexo Therapeutics is an oncology drug-discovery company using covalent ligand discovery and chemical biology.
- 30
- Company
- Watertown, MA, USUnited States
Nexo Therapeutics is an oncology drug-discovery company using covalent ligand discovery and chemical biology.
nexotx.comCrawled Oct 15, 2026
Calico Life Sciences LLC is a clinical-stage biotechnology organization focused on aging and age-related diseases.
Vice President and Head of Business Development
The lobby entrance is located on the first floor of the parking garage attached to the building, accessible from Forge Road (the road between 500 Forge Road and the Home Depot store). From the lobby, take the elevator to the third floor.
The company uses chemical biology and pharmacology, enabled by covalent ligand discovery across all nucleophilic amino acids, to target undruggable targets.
Nexo Therapeutics, Inc.’s privacy statement explains how it collects, uses, and discloses personal information from its website and other websites that link to the policy.
Nexo Therapeutics, Inc. provides a website governed by its Terms of Service. By using the website, visitors agree to the terms.
Calico and Nexo collaborate to discover and develop small-molecule therapies targeting age-related diseases. The partnership leverages Calico’s expertise in aging biology and Nexo’s integrated platform for drug discovery. The goal is to accelerate the translation of research insights into potential new treatments.
May 2026nexotx.comNews article
Nexo Therapeutics secures **$60 million in Series A funding** to advance its drug development platform. The company partners with **MD Anderson Cancer Center** for research collaboration, focusing on challenging therapeutic targets. Founders designed the name to reflect its innovative approach to drug discovery.
Aug 2023BioWorldNews article
Nexo Therapeutics secures **$60 million in Series A funding** led by Versant Ventures to advance its **covalent chemistry-based cancer drug research**. The company focuses on expanding the therapeutic potential of amino acids in drug development. Nexo’s approach targets novel mechanisms for treating cancer, leveraging covalent binding strategies to improve efficacy.
Jul 2023MedCity NewsNews article
Nexo Therapeutics secures $60 million in Series A funding to advance its small molecule oncology platform. The company focuses on developing novel treatments for cancer. Investors back its drug discovery pipeline targeting unmet needs in oncology.
Jul 2023Pharmaceutical TechnologyNews article